
Dermatology
Latest News
Latest Videos

Shorts










Podcasts
More News

Real-world claims show dupilumab was tied to a 33%-52% lower risk of atopic march progression vs systemic corticosteroids in children with AD.

Once-daily roflumilast cream 0.05% was well tolerated in infants 3 to <24 months with AD, with 34.4% reaching vIGA-AD success at week 4.

Oral icotrokinra kept PASI 90 rates at ≥72% and IGA 0/1 at ≥70% from week 64 to 112 in ICONIC-LEAD, with no new safety signals.

Oral icotrokinra sustained scalp, genital, and hand/foot psoriasis clearance through week 112 in ICONIC-TOTAL, with no new safety signals.

A 16-month-old with recurrent otitis media developed a spreading unilateral rash on her hip and thigh during antibiotic treatment. PCR testing confirmed herpes zoster, an uncommon diagnosis in young, vaccinated children.

Upadacitinib showed continued facial and body repigmentation in NSV through week 76, with numerically higher responses when combined with NB-UVB.

Can you guess the diagnosis?

The approval is based on BRAVE-AA-PEDS, in which 42% of adolescents receiving baricitinib 4 mg achieved at least 80% scalp hair coverage at week 36 vs 5% with placebo.

The FDA accepted the dersimelagon NDA with priority review for EPP and XLP; a decision on the oral MC1R agonist is expected by February 2027.

Children with atopic dermatitis have higher ADHD risk, particularly with early, severe disease and sleep disturbance, a review found.

Baseline severity and clinical phenotype may help predict response to systemic therapy in children with alopecia areata.

Can you guess the diagnosis?

Can you guess the diagnosis?

Phase 3 data show lebrikizumab improved skin clearance, itch, and quality of life in children with moderate-to-severe atopic dermatitis.

A Rutgers-led study finds teens who follow beauty influencers or watch tutorials use significantly more personal care products, many containing endocrine-disrupting chemicals.

New approvals and emerging data are expanding nonsteroidal topical treatment options for several chronic pediatric skin conditions.

Adverse childhood experiences may affect pediatric skin disease risk and outcomes, but researchers say evidence remains limited.










